Main container

Danno endoteliale, espresso come variazione di Syndecan-1, in chirurgia del rachide con sanguinamento maggiore: studio pilota prospettico osservazionale

Title
Danno endoteliale, espresso come variazione di Syndecan-1, in chirurgia del rachide con sanguinamento maggiore: studio pilota prospettico osservazionale
Code
GlicOrtho
Type
Osservazionale
Start Year
2022
Status
In Corso

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more